DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

Phase 2

Completed

Conditions: Haemostasis
Haemophilia A

Interventions: Drug: Concizumab
Drug: Turoctocog alfa

First Posted Date: 2017-06-22

Last Posted Date: 2021-11-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT03196297

Locations: 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

Phase 2

Completed

Conditions: Haemophilia B With Inhibitors
Congenital Bleeding Disorder
Haemophilia A With Inhibitors

Interventions: Drug: Concizumab
Drug: Eptacog alfa

First Posted Date: 2017-06-22

Last Posted Date: 2021-10-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 26

Registration Number: NCT03196284

Locations: 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom

Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Liraglutide
Drug: Semaglutide

First Posted Date: 2017-06-19

Last Posted Date: 2019-10-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 577

Registration Number: NCT03191396

Locations: 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom

Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function

Phase 1

Completed

Conditions: Adult Growth Hormone Deficiency
Growth Hormone Disorder
Growth Hormone Deficiency in Children

Interventions: Drug: Somapacitan

First Posted Date: 2017-06-14

Last Posted Date: 2020-04-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 44

Registration Number: NCT03186495

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa

First Posted Date: 2017-06-07

Last Posted Date: 2021-11-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 10

Registration Number: NCT03179748

Locations: 🇲🇽
Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico

A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Insulin degludec/liraglutide
Drug: Insulin degludec

First Posted Date: 2017-06-05

Last Posted Date: 2020-03-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 453

Registration Number: NCT03175120

Locations: 🇭🇰
Novo Nordisk Investigational Site, Shatin, New Territories, Hong Kong

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Insulin degludec/liraglutide
Drug: Insulin degludec
Drug: Liraglutide

First Posted Date: 2017-06-01

Last Posted Date: 2022-12-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 720

Registration Number: NCT03172494

Locations: 🇨🇳
Novo Nordisk Investigational Site, Fuzhou, China

Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2
Healthy

Interventions: Drug: Placebo
Drug: semaglutide

First Posted Date: 2017-05-08

Last Posted Date: 2017-05-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 58

Registration Number: NCT03144271

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide
Drug: Canagliflozin
Drug: Placebo (canagliflozin)
Drug: Placebo (semaglutide)

First Posted Date: 2017-05-02

Last Posted Date: 2020-01-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 788

Registration Number: NCT03136484

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wellingborough, United Kingdom

Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity

Phase 1

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: NNC9204-1706 A
Drug: Placebo

First Posted Date: 2017-03-30

Last Posted Date: 2018-10-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 34

Registration Number: NCT03095807

Locations: 🇺🇸
Novo Nordisk Investigational Site, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy